0000950170-23-032062.txt : 20230706 0000950170-23-032062.hdr.sgml : 20230706 20230706171123 ACCESSION NUMBER: 0000950170-23-032062 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230705 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230706 DATE AS OF CHANGE: 20230706 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tivic Health Systems, Inc. CENTRAL INDEX KEY: 0001787740 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 814016391 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41052 FILM NUMBER: 231074382 BUSINESS ADDRESS: STREET 1: 25821 INDUSTRIAL BLVD., SUITE 100 CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: (888)276-6888 MAIL ADDRESS: STREET 1: 25821 INDUSTRIAL BLVD., SUITE 100 CITY: HAYWARD STATE: CA ZIP: 94545 8-K 1 tivc-20230705.htm 8-K 8-K
false0001787740--12-3100017877402023-07-052023-07-05

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 05, 2023

 

 

Tivic Health Systems, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41052

81-4016391

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

25821 Industrial Blvd.,

Suite 100

 

Hayward, California

 

94545

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 888 276-6888

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

TIVC

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On July 5, 2023, Tivic Health Systems, Inc. (the “Company”) amended its Amended and Restated Bylaws (the “Bylaws”) to (i) revise Article II, Section 2.5 of the Bylaws to incorporate those requirements set forth in Rule 14a-19 of the Securities Exchange Act of 1934, as amended, as recently implemented by the SEC; and (ii) to revise Article II, Section 2.8 of the Bylaws to decrease the quorum threshold necessary to conduct business at stockholder meetings of the Company to one-third of the capital stock issued and outstanding and entitled to vote at the meeting. The foregoing amendments are set forth in a Certificate of Amendment to the Bylaws.

 

Pursuant to Article XI of the Bylaws, stockholder approval was not required to amend the Bylaws.

 

The foregoing summary of the provisions of the Certificate of Amendment does not purport to be complete, and is qualified in its entirety by reference to the complete text of the Certificate of Amendment, a copy of which is attached as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

 

Description

3.1

Certificate of Amendment to the Amended and Restated Bylaws of the Company, dated July 5, 2023.

104

Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101).

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

TIVIC HEALTH SYSTEMS, INC.

 

 

 

 

Date:

July 6, 2023

By:

/s/ Jennifer Ernst

 

 

 

Name: Jennifer Ernst
Title: Chief Executive Offive

 


EX-3.1 2 tivc-ex3_1.htm EX-3.1 EX-3.1

Exhibit 3.1

 

CERTIFICATE OF AMENDMENT

 

TO THE

 

AMENDED AND RESTATED BYLAWS

 

OF

 

TIVIC HEALTH SYSTEMS, INC.

 

(a Delaware corporation)

 

The undersigned hereby certifies that:

1.
She is the duly elected, qualified and acting Secretary of Tivic Health Systems, Inc., a Delaware corporation (the “Company”), and in charge of the corporate minute book and corporate records of the Company.

 

2.
On July 5, 2023, the Board of Directors, pursuant to its authority granted in Article XI of the Amended and Restated Bylaws of the Company (the “Bylaws”), approved amendments to the Bylaws, as follows:

 

2.1
Article II, Section 2.5 of the Bylaws is amended and restated in its entirety to read as follows:

 

2.5 ADVANCE NOTICE PROCEDURES FOR NOMINATIONS OF DIRECTORS.

(a) Nominations of any person for election to the Board at an annual meeting or at a special meeting (but, in the case of a special meeting, only if the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling such special meeting) may be made at such meeting only (i) by or at the direction of the Board or any committee thereof, or (ii) by a stockholder who (A) was a stockholder of record of the Corporation (and, with respect to any beneficial owner, if different, on whose behalf such nomination is proposed to be made, only if such beneficial owner was the beneficial owner of shares of the Corporation) both at the time of giving the notice provided for in this Section 2.5 and at the time of the meeting, (B) is entitled to vote at the meeting and (C) has complied with both this Section 2.5 and the requirements set forth in Rule 14a-19 of the Exchange Act as to such nomination. The foregoing clause (ii) shall be the exclusive means for a stockholder to make any nomination of a person or persons for election to the Board to be considered by the stockholders at an annual meeting or special meeting.

(b) Without qualification, for a stockholder to make any nomination of a person or persons for election to the Board at an annual meeting, the stockholder must (i) provide Nomination Timely Notice (as defined below) thereof in writing and in proper form to the secretary of the Corporation, (ii) provide any updates or supplements to such notice at the times and in the forms required by this Section 2.5 and Rule 4a-19 of the Exchange Act, and (iii) complies with those procedures set forth in Rule 4a-19 of the Exchange Act. To be timely, a stockholder’s notice must be delivered to, or mailed and received by the Secretary at, the principal executive offices of the Corporation not less than ninety (90) days nor more than one hundred twenty (120) days prior to the first anniversary of the preceding year’s annual meeting; provided, however, that if the date of the annual meeting is more than thirty (30) days before or after such anniversary date, notice by the stockholder

- 1 -

DOCPROPERTY DocID \* MERGEFORMAT 125098-00000001/7050281.1


Exhibit 3.1

to be timely must be so delivered, or mailed and received, not earlier than the close of business on the one hundred twentieth (120th) day prior to such annual meeting and not later than the later of the close of business on the ninetieth (90th) day prior to such annual meeting and the close of business on the tenth (10th) day following the day on which public disclosure of the date of such annual meeting was first made (such notice within such time periods, “Nomination Timely Notice”). Notwithstanding anything in this paragraph to the contrary, in the event that the number of directors to be elected to the Board at an annual meeting is increased effective after the time period for which nominations would otherwise by due under this paragraph (b) and there is no public announcement by the Corporation naming the nominees for the additional directorships at least one hundred (100) days prior to the first anniversary of the preceding year’s annual meeting, a stockholder’s notice required by paragraph (b) of this Section 2.5 shall also be considered timely, but only with respect to nominees for the additional directorships, if it shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the Corporation. Without qualification, if the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling such special meeting, then for a stockholder to make any nomination of a person or persons for election to such position(s) as specified in the notice of the special meeting, the stockholder must (i) provide timely notice thereof in writing and in proper form to the secretary of the Corporation at the principal executive offices of the Corporation and (ii) provide any updates or supplements to such notice at the times and in the forms required by this Section 2.5. To be timely, a stockholder’s notice for nominations to be made at a special meeting must be delivered to, or mailed and received at, the principal executive offices of the Corporation not earlier than the close of business on the one hundred twentieth (120th) day prior to such special meeting and not later than the later of the close of business on the ninetieth (90th) day prior to such special meeting and the close of business on the tenth (10th) day following the day on which public disclosure (as defined in Section 2.4(i) of these bylaws) of the date of such special meeting was first made. In no event shall any adjournment or postponement of an annual meeting or special meeting or the announcement thereof commence a new time period (or extend any time period) for the giving of a stockholder’s notice as described above.

(c) To be in proper form for purposes of this Section 2.5, a stockholder’s notice to the secretary of the Corporation shall set forth:

(i) As to each Nominating Person (as defined below), the Stockholder Information (as defined in Section 2.4(c)(i) of these bylaws), except that for purposes of this Section 2.5, the term “Nominating Person” shall be substituted for the term “Proposing Person” in all places it appears in Section 2.4(c)(i);

(ii) As to each Nominating Person, any Disclosable Interests (as defined in Section 2.4(c)(ii), except that for purposes of this Section 2.5 the term “Nominating Person” shall be substituted for the term “Proposing Person” in all places it appears in Section 2.4(c)(ii) and the disclosure in clause (L) of Section 2.4(c)(ii) shall be made with respect to the election of directors at the meeting), provided, however, that Disclosable Interests shall not include any such disclosures with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Nominating Person solely as a result of being the stockholder directed to prepare and submit the notice required by these bylaws on behalf of a beneficial owner; and;

(iii) As to each person whom a Nominating Person proposes to nominate for election as a director, (A) all information with respect to such proposed nominee that would be required to be set forth in a stockholder’s notice pursuant to this Section 2.5 if such proposed nominee were a Nominating Person, (B) all information relating to such proposed nominee that is required to be disclosed in a proxy statement or other

- 2 -

DOCPROPERTY DocID \* MERGEFORMAT 125098-00000001/7050281.1


Exhibit 3.1

filings required to be made in connection with solicitations of proxies for election of directors in a contested election pursuant to Section 14(a) under the Exchange Act (including, without limitation, such proposed nominee’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected), (C) a description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings during the past three (3) years, and any other material relationships, between or among any Nominating Person, on the one hand, and each proposed nominee, his or her respective affiliates and associates and any other persons with whom such proposed nominee (or any of his or her respective affiliates and associates) is Acting in Concert (as defined in Section 2.4(e) of these bylaws), on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Item 404 under Regulation S-K if such Nominating Person were the “registrant” for purposes of such rule and the proposed nominee were a director or executive officer of such registrant (the disclosures to be made pursuant to the foregoing clauses (A) through (C) are referred to as “Nominee Information”), (D) a representation that the Nominating Person is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to propose such nomination, (E) a representation that the Nominating Person intends to solicit the holders of shares representing at least 67% of the voting power of shares entitled to vote on the election of directors in support of director nominees other than the Company's nominees and (F) a completed and signed questionnaire, representation and agreement as provided in Section 2.5(g); and

(iv) The Corporation may require any proposed nominee to furnish such other information (A) as may reasonably be required by the Corporation to determine the eligibility of such proposed nominee to serve as an independent director of the Corporation in accordance with the Corporation’s Corporate Governance Guidelines or (B) that could be material to a reasonable stockholder’s understanding of the independence or lack of independence of such proposed nominee.

(d) For purposes of this Section 2.5, the term “Nominating Person” shall mean (i) the stockholder providing the notice of the nomination proposed to be made at the meeting, (ii) the beneficial owner or beneficial owners, if different, on whose behalf the notice of the nomination proposed to be made at the meeting is made, (iii) any affiliate or associate of such stockholder or beneficial owner and (iv) any other person with whom such stockholder or such beneficial owner (or any of their respective affiliates or associates) is Acting in Concert.

(e) A stockholder providing notice of any nomination proposed to be made at a meeting shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section 2.5 and Rule 14a-19 of the Exchange Act shall be true and correct as of the record date for determining stockholders entitled to notice of the meeting and as of the date that is ten (10) business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the secretary of the Corporation at the principal executive offices of the Corporation not later than five (5) business days after the record date for determining stockholders entitled to notice of the meeting (in the case of the update and supplement required to be made as of the record date), and not later than eight (8) business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of ten (10) business days prior to the meeting or any adjournment or postponement thereof).

(f) Notwithstanding anything in these bylaws to the contrary, no person shall be eligible for election as a director of the Corporation unless nominated in accordance with

- 3 -

DOCPROPERTY DocID \* MERGEFORMAT 125098-00000001/7050281.1


Exhibit 3.1

this Section 2.5, except as otherwise expressly provided in any applicable rule or regulation promulgated under the Exchange Act. The presiding officer at any meeting of stockholders shall have the power and duty to (a) determine that a nomination was not properly made in accordance with this Section 2.5 (including whether the stockholder or beneficial owner, if any, on whose behalf the nomination was made, solicited or is part of a group which solicited) or did not so solicit, as the case may be, sufficient proxies or votes in support of such stockholder’s nomination in compliance with such stockholder’s representation as required by clause (c)(iii)(E) of this Section 2.5); and (b) if any proposed nomination was not made in compliance with this Section 2.5 to declare such determination to the meeting that the defective nomination shall be disregarded.

(g) To be eligible to be a nominee for election as a director of the Corporation, the proposed nominee must deliver (in accordance with the time periods prescribed for delivery of notice under this Section 2.5) to the secretary of the Corporation at the principal executive offices of the Corporation a written questionnaire with respect to the background and qualification of such proposed nominee (which questionnaire shall be provided by the secretary upon written request) and a written representation and agreement (in form provided by the secretary upon written request) that such proposed nominee (i) is not and will not become a party to (A) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation or (B) any Voting Commitment that could limit or interfere with such proposed nominee’s ability to comply, if elected as a director of the Corporation, with such proposed nominee’s fiduciary duties under applicable law, (ii) is not, and will not become a party to, any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed to the Corporation and (iii) in such proposed nominee’s individual capacity and on behalf of the stockholder (or the beneficial owner, if different) on whose behalf the nomination is made, would be in compliance, if elected as a director of the Corporation, and will comply with applicable publicly disclosed corporate governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines of the Corporation.

(h) In addition to the requirements of this Section 2.5 with respect to any nomination proposed to be made at a meeting, each Nominating Person shall comply with all applicable requirements of the Exchange Act, including Rule 14a-19 thereof, with respect to any such nominations.

(i) Notwithstanding the foregoing provisions of this Section 2.5, unless otherwise required by law, if the stockholder (or a qualified representative of the stockholder) does not appear at the meeting to present the proposed nomination, such proposed nomination shall not be considered, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Section 2.5, to be considered a qualified representative of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting.

 

2.2
Article II, Section 2.8 of the Bylaws is amended and restated in its entirety to read as follows:

 

2.8 QUORUM.

- 4 -

DOCPROPERTY DocID \* MERGEFORMAT 125098-00000001/7050281.1


Exhibit 3.1

Unless otherwise provided by law, the certificate of incorporation or these bylaws, the holders of one-third of the capital stock issued and outstanding and entitled to vote at the meeting, present in person, or by remote communication, if applicable, or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. A quorum, once established at a meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum. If, however, a quorum is not present or represented at any meeting of the stockholders, then either (a) the chairperson of the meeting or (b) a majority in voting power of the stockholders entitled to vote thereon, present in person, or by remote communication, if applicable, or represented by proxy, shall have power to adjourn the meeting from time to time in the manner provided in Section 2.9 of these bylaws until a quorum is present or represented. At such adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the meeting as originally noticed.

 

3.
In all other respects, the Bylaws are hereby ratified and confirmed and shall remain in full force and effect.

IN WITNESS WHEREOF, the Company has executed this Certificate of Amendment to the Amended and Restated Bylaws of Tivic Health Systems, Inc. as of July 5, 2023.

TIVIC HEALTH SYSTEMS, INC.

By:

/s/ Jennifer Ernst

Name:

Its:

Jennifer Ernst
Secretary

 

- 5 -

DOCPROPERTY DocID \* MERGEFORMAT 125098-00000001/7050281.1


EX-101.PRE 3 tivc-20230705_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 4 tivc-20230705.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 tivc-20230705_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Current Fiscal Year End Date Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information
Jul. 05, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Current Fiscal Year End Date --12-31
Document Period End Date Jul. 05, 2023
Entity Registrant Name Tivic Health Systems, Inc.
Entity Central Index Key 0001787740
Entity Emerging Growth Company true
Securities Act File Number 001-41052
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-4016391
Entity Address, Address Line One 25821 Industrial Blvd.,
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Hayward
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94545
City Area Code 888
Local Phone Number 276-6888
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol TIVC
Security Exchange Name NASDAQ
XML 7 tivc-20230705_htm.xml IDEA: XBRL DOCUMENT 0001787740 2023-07-05 2023-07-05 false 0001787740 --12-31 8-K 2023-07-05 Tivic Health Systems, Inc. DE 001-41052 81-4016391 25821 Industrial Blvd., Suite 100 Hayward CA 94545 888 276-6888 false false false false Common Stock, par value $0.0001 per share TIVC NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports tivc-20230705.htm tivc-20230705.xsd tivc-20230705_lab.xml tivc-20230705_pre.xml tivc-ex3_1.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tivc-20230705.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "contextCount": 1, "dts": { "inline": { "local": [ "tivc-20230705.htm" ] }, "labelLink": { "local": [ "tivc-20230705_lab.xml" ] }, "presentationLink": { "local": [ "tivc-20230705_pre.xml" ] }, "schema": { "local": [ "tivc-20230705.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tivc", "nsuri": "http://www.tivichealthsystems.com/20230705", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tivc-20230705.htm", "contextRef": "C_c3d21203-d615-4084-a63b-1d53fa790aaf", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tivc-20230705.htm", "contextRef": "C_c3d21203-d615-4084-a63b-1d53fa790aaf", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.tivichealthsystems.com/20230705/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0000950170-23-032062-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-032062-xbrl.zip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end